Slowing the spread of treatment failure to artemisinin-based combination therapies in Uganda
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The multiple emergences and continuing spread of partially artemisinin-resistant Plasmodium falciparum in Africa, where about 95% of malaria occurs, is a health challenge that requires urgent attention. The World Health Organization has developed a resistance response strategy that centers on enhancing surveillance, reducing drug pressure, and evaluating novel tools to slow resistance evolution which includes the deployment of multiple first-line therapies (MFT). Developing a specific resistance response is critical for Uganda, where four pfkelch13 mutations are at local allele frequencies >0.20.
Methods
Using a previously validated Uganda-calibrated individual-based mathematical model of P. falciparum transmission and evolution, we evaluated 53 public-sector deployment strategies for artemisinin-based combination therapies (ACTs) aimed at reducing treatment failure and slowing the spread of pfkelch13 alleles from 2025 to 2031. We assume that artemether-lumefantrine (AL) will continue to be used in the private sector.
Results
A change of first-line therapy from AL to artesunate-amodiaquine (ASAQ) is projected to reduce treatment failures by 34.7% to 38.3% (90% range of simulation outcomes) over six years, while a change to dihydroartemisinin-piperaquine (DHA-PPQ) is projected to reduce treatment failures over the same period by 10.0% to 12.9%. This pessimistic projection for DHA-PPQ deployment rests on a model assumption – supported by clinical data from SE Asia – that piperaquine resistance evolution will lead to high rates of treatment failure. Optimal MFT deployments and cycling approaches are projected to reduce treatment failure counts by ∼36% when compared to status quo AL use, an outcome similar to country-wide ASAQ deployment. MFT and cycling approaches are predicted to work best when ASAQ is recommended for a majority of malaria cases and DHA-PPQ for a smaller proportion of cases. Deployment of the triple ACT artemether-lumefantrine-amodiaquine has the potential to reduce treatment failures by ∼42% if enacted immediately.
Conclusions
Increased adoption of and coverage with ASAQ is projected to play a large role in reducing malaria treatment failure counts in Uganda over the next six years. With continued AL use in the private sector, ASAQ and DHA-PPQ deployment in the public sector creates a public-private MFT mix of antimalarial use. DHA-PPQ deployment should be accompanied by real-time molecular surveillance for piperaquine-resistant genotypes.
